Intravenous ibandronate treatment in glucocorticoid-induced osteoporosis: a randomized controlled clinical trial
- VernacularTitle:静脉伊班膦酸钠冲击治疗类固醇性骨质疏松症的临床对照研究
- Author:
Han LI
;
Zhangsuo LIU
- Publication Type:Journal Article
- Keywords:
Glucocorticoids;
Osteoporosis;
Bone density;
Ibandronale
- From:
Chinese Journal of Nephrology
1997;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the safety and efficacy of intravenous ibandronale in treating glucocorticoid-induced osteoporosis. Methods One hundred and fifty-three glucocorticoid-induced osteoporosis patients were randomly divided into three groups: (1)control group (C group, 49 patients). (2) ibandronate group (1 group, 52 patients): Patients received intraveous injection of ibandronate (2 mg)once three mouths. (3)alfacaleidol group (R group, 52 patients): 0.25 ?g Rocaltrol once a day for six months. Each patient of the three groups received a daily 600 mg calcium supplement for six months. The efficacy was assessed by determining the subsequent change in bone mass density (BMD) of lumbar spine and femoral neck, intact parathyroid hormone (iPTH), serum calcium, serum phosphorus, serum alkaline phosphatase (AKP). Results (1) At the end of the trial, there was a significant increase of BMD of lumbar spine and femoral neck in I group and R group compared with the C group (P
